KRAS and HDAC3 Inhibitor Combination for Lung Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for KRAS, LKB1 mutant lung cancer, particularly those resistant to KRAS inhibitors, face challenges due to limited understanding of HDAC3's role in tumorigenesis and the lack of selective HDAC inhibitors, leading to suboptimal therapeutic responses.
Innovation Solution
The development of pharmaceutical compositions comprising KRAS inhibitors and HDAC inhibitors, specifically HDAC3 inhibitors like entinostat, to overcome resistance in KRAS, LKB1 mutant lung cancer by co-administering these agents to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If KRAS inhibitors are used to treat KRAS, LKB1 mutant lung cancer, then initial therapeutic response is achieved, but resistance develops over time
Solution Approach 1:
The patent applies preliminary action by identifying and targeting HDAC3 as a resistance mechanism before it fully develops. By pre-treating with HDAC inhibitors in combination with KRAS inhibitors, the therapy prevents resistance from establishing itself, thereby maintaining therapeutic response over time. This is achieved through combination therapy that simultaneously attacks both the primary oncogenic driver (KRAS) and the emerging resistance mechanism (HDAC3).
Solution Approach 2:
HDAC3 acts as an intermediary mechanism that mediates resistance to KRAS inhibitors. The patent identifies HDAC3 as the molecular mediator that enables tumor cells to resist KRAS inhibition, and by targeting HDAC3 with specific inhibitors, the therapy reverses this resistance mediation and restores sensitivity to KRAS inhibition.
2Reliability
If HDAC inhibitors are used to treat solid tumors, then some therapeutic effect is achieved, but efficacy is limited compared to hematopoietic malignancies
Solution Approach 1:
The patent applies local quality by transitioning from non-specific HDAC inhibition to HDAC3-specific inhibition. Instead of using pan-HDAC inhibitors that work somewhat better in hematopoietic malignancies, the therapy uses HDAC3-selective inhibitors that target a specific HDAC isoform with a distinct role in solid tumor resistance. This specificity allows the HDAC inhibitor to be effectively adapted to solid tumor contexts, particularly KRAS, LKB1 mutant lung cancer, where HDAC3 drives resistance mechanisms.
Solution Approach 2:
The patent applies parameter changes by altering the selectivity parameter of HDAC inhibition. Rather than using non-selective HDAC inhibitors, the therapy changes the parameter of HDAC inhibition to be HDAC3-specific. This parameter change enables the HDAC inhibitor to function effectively in solid tumors by targeting the specific HDAC3-mediated resistance pathway that is active in KRAS, LKB1 mutant lung cancer.
3Adaptability or versatility
If pan-HDAC inhibitors are used, then multiple HDACs are inhibited, but therapeutic potential is limited compared to selective HDAC inhibitors
Solution Approach 1:
The patent applies the taking out principle by extracting HDAC3 from the broader HDAC family and focusing inhibition specifically on this single isoform. Instead of inhibiting multiple HDACs with pan-HDAC inhibitors, the therapy extracts and targets only HDAC3, which is the specific isoform driving resistance in KRAS, LKB1 mutant lung cancer. This extraction of HDAC3 inhibition from the broader HDAC family context enables more potent and targeted therapeutic response.
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising KRAS inhibitors and HDAC inhibitors and methods of administering KRAS inhibitors and HDAC inhibitors for the treatment/prevention of cancer. In particular, an HDAC inhibitor is administered to overcome KRAS inhibitor resistance in KRAS, LKB1 mutant lung cancer.